A citation-based method for searching scientific literature

Robert Ritzel, Ronan Roussel, Andrea Giaccari, Jiten Vora, Claire Brulle-Wohlhueter, Hannele Yki-Järvinen. Diabetes Obes Metab 2018
Times Cited: 47







List of co-cited articles
330 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
189
48



More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
105
42


Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
303
38

Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Fang Liz Zhou, Fen Ye, Paulos Berhanu, Vineet E Gupta, Rishab A Gupta, Jennifer Sung, Jukka Westerbacka, Timothy S Bailey, Lawrence Blonde. Diabetes Obes Metab 2018
49
34


Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
146
27



Basal insulin and cardiovascular and other outcomes in dysglycemia.
Hertzel C Gerstein, Jackie Bosch, Gilles R Dagenais, Rafael Díaz, Hyejung Jung, Aldo P Maggioni, Janice Pogue, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
25


Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.
Jeremy Pettus, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Jukka Westerbacka, Rachele Berria, Javier Jimenez, Björn Eliasson, Irene Hramiak, Timothy Bailey,[...]. Diabetes Ther 2019
36
30

Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
Richard M Bergenstal, Timothy S Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J Ahmann. Diabetes Care 2017
73
19

Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sean D Sullivan, Timothy S Bailey, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Ronald Preblick, Jukka Westerbacka, Rishab A Gupta, Lawrence Blonde. Diabetes Obes Metab 2018
46
19

Identification of barriers to insulin therapy and approaches to overcoming them.
David Russell-Jones, Frans Pouwer, Kamlesh Khunti. Diabetes Obes Metab 2018
104
19

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
244
19


Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
241
17


Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
228
17




Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
17


New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C Riddle. Diabetes Care 2015
117
14

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
14

Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
K Khunti, A Nikolajsen, B L Thorsted, M Andersen, M J Davies, S K Paul. Diabetes Obes Metab 2016
160
14



Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
14

Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
Timothy S Bailey, Jasmanda Wu, Fang L Zhou, Rishab A Gupta, Arjun A Menon, Paulos Berhanu, Jukka Westerbacka, John Van Vleet, Lawrence Blonde. Diabetes Obes Metab 2019
16
43


Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr. Diabetes Obes Metab 2017
75
12

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
R H A Becker, I Nowotny, L Teichert, K Bergmann, C Kapitza. Diabetes Obes Metab 2015
79
12

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.
Dídac Mauricio, Luigi Meneghini, Jochen Seufert, Laura Liao, Hongwei Wang, Liyue Tong, Anna Cali, Peter Stella, Paulo Carita, Kamlesh Khunti. Diabetes Obes Metab 2017
66
12


Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.
Nick Freemantle, Engels Chou, Christian Frois, Daisy Zhuo, Walter Lehmacher, Aleksandra Vlajnic, Hongwei Wang, Hsing-Wen Chung, Quanwu Zhang, Eric Wu,[...]. BMJ Open 2016
38
15

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study.
Robert Ritzel, Stewart B Harris, Helen Baron, Hermes Florez, Ronan Roussel, Melanie Espinasse, Isabel Muehlen-Bartmer, Nianxian Zhang, Monica Bertolini, Claire Brulle-Wohlhueter,[...]. Diabetes Care 2018
32
18


Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Tim Heise, Ulrike Hövelmann, Leszek Nosek, Lidia Hermanski, Susanne G Bøttcher, Hanne Haahr. Expert Opin Drug Metab Toxicol 2015
81
12



Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
124
12


Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
281
12

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Timothy S Bailey, Fang L Zhou, Rishab A Gupta, Ronald Preblick, Vineet E Gupta, Paulos Berhanu, Lawrence Blonde. Diabetes Obes Metab 2019
19
31


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.